Navigation Links
Discuss Early Results of the DIAN Trial at CBI's 6th Annual Alzheimer's Drug Development Summit

WOBURN, Mass., Aug. 21, 2012 /PRNewswire/ -- CBI recently added John C. Morris M.D., a Friedman Distinguished Professor of Neurology and Director at Knight Research Center of Washington University School of Medicine, to the prestigious speaker roster for CBI's 6th Annual Alzheimer's Drug Development Summit in Philadelphia.

This December 11-12, attendees come together during the session: Future Perspective from the Dominantly Inherited Alzheimer Network (DIAN) ( to discuss the early results from the trial as well as review key highlights and information:

  • Analyze the importance of the DIAN trial to Alzheimer's clinical trials
  • Discuss the therapies being evaluated in the DIAN trial and study design
  • Understand the initial results of the DIAN clinical trial and forward goals

With a strong agenda filled with expert speakers reflecting on recent clinical trial implications and current research on translational and preventative treatments for Alzheimer's, CBI's 6th Annual Alzheimer's Drug Development Summit offers industry leaders an educational platform to continue the dialogue of research findings and continue to advance towards the prevention and treatment of Alzheimer's disease.

CBI, an Advanstar company, is the leading provider of market-driven, unbiased conferences for the pharmaceutical, biotechnology, medical device and healthcare industries. CBI offers specialized information presented in interactive formats by thought leaders and regulators.

Contact: Kristina Weljkovic
Phone number: 339-298-2285
Email address:

This press release was issued through eReleases® Press Release Distribution. For more information, visit  

Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. AAAS To Host Live Online Discussion On 2013 U.S. Federal R&D Budget
2. Atlanta LASIK Surgeon Dr. Ashraf Releases YouTube Videos Featuring Patient Testimonials and Discussion of Common Eye Treatments
3. TAKE Solutions Brings Together Leading Experts and TAKE Customers at “Converge 2012” to Discuss Business
4. Expert Meeting Discusses Testing of Oxitec Transgenic Mosquitoes in Panama
5. NIRI San Diego May Meeting: Seasoned IROs Discuss "Tips & Tactics for Establishing and Maintaining A Successful Investor Relations Program"
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2011 Financial Results on March 12, 2012
7. Researchers peek at the early evolution of sex chromosomes
8. Butamax Early Adopters Group surpasses capacity targets with addition of Big River; Membership represents 11 production facilities and nearly 900 million gallons of ethanol capacity
9. Corporate Venturing and Early-Stage Financing in the Spotlight at BioTrinity
10. CSL Behring Study Confirms Early Treatment with Berinert® Provides Faster Resolution of Acute Hereditary Angioedema Symptoms
11. Sequenom Announces 2011 Operational Highlights and Early 2012 Outlook
Post Your Comments:
(Date:11/25/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: ... prospects remain fundamentally strong and highlights the following ... received DSMB recommendation to continue the ZoptEC Phase ... the final interim efficacy and safety data ... men with heavily pretreated castration- and Taxane-resistant prostate ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman and ... early in their initial angel funding process. Now, they are paying it forward ... make early stage investments in the microbiome space. In this, they join ...
(Date:11/24/2015)... , Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: ... Conference in New York on Wednesday, December ... Helen Torley , president and CEO, will provide a corporate overview. ... New York at 1:00 p.m. ET/10:00 a.m. PT . ... investor relations, will provide a corporate overview. --> th ...
(Date:11/24/2015)... 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: ... behalf of the Toronto Stock Exchange, confirms that as ... no corporate developments that would cause the recent movements ... --> About Aeterna Zentaris Inc. ... --> Aeterna Zentaris is a specialty biopharmaceutical company ...
Breaking Biology Technology:
(Date:11/11/2015)... , Nov. 11, 2015   MedNet Solutions , ... spectrum of clinical research, is pleased to announce that it ... Clinical Trials (PCT) event, to be held November 17-19 ... able to view live demonstrations of iMedNet ... learn how iMedNet has been able to deliver ...
(Date:11/4/2015)... ALBANY, New York , November 4, 2015 /PRNewswire/ ... According to a new market report published by Transparency ... Size, Share, Growth, Trends and Forecast 2015 - 2022", ... value of US$ 30.3 bn by 2022. The market ... during the forecast period from 2015 to 2022. Rising ...
(Date:10/29/2015)... 2015  Rubicon Genomics, Inc., today announced an ... its DNA library preparation products, including the ThruPLEX ... Plasma-seq kit. ThruPLEX Plasma-seq has been optimized for ... libraries for liquid biopsies--the analysis of cell-free circulating ... in cancer and other conditions. Eurofins Scientific is ...
Breaking Biology News(10 mins):